Gabapentin (Epilepsy)

Table   Graphic  
individual studies
OutcomeTE95% CIn casesn exposedkPub. bias Congenital malformations All congenital malformations (majors, minors, majors and minors, or unspecified) Dean (Gabapentin), 2002 Morrow (Gabapentin) (Controls unexposed, sick), 2006 Mawer (Gabapentin) (Controls unexposed, sick), 2010 Vajda (Gabapentin) (Controls unexposed, sick), 2013 Tomson (Gabapentin), 2018 51.34[0.42; 4.34]9784not evaluable Major congenital malformations Dean (Gabapentin), 2002 Morrow (Gabapentin) (Controls unexposed, sick), 2006 Mawer (Gabapentin) (Controls unexposed, sick), 2010 Vajda (Gabapentin) (Controls unexposed, sick), 2013 Tomson (Gabapentin), 2018 51.48[0.46; 4.79]9284serious Congenital heart defects Morrow (Gabapentin) (Controls exposed to Lamotrigine, sick), 2006 15.36[0.58; 49.42]531not evaluable Atrial septal defect 0----- Digestive system anomalies Morrow (Gabapentin) (Controls exposed to Lamotrigine, sick), 2006 13.01[0.15; 59.66]331not evaluable Eye defects Dean (Gabapentin), 2002 14.85[0.09; 267.23]61not evaluable Hypospadias Morrow (Gabapentin) (Controls exposed to Lamotrigine, sick), 2006 11.62[0.09; 29.34]631not evaluable Limb defects Morrow (Gabapentin) (Controls exposed to Lamotrigine, sick), 2006 14.23[0.20; 89.96]231not evaluable Minor congenital malformations Dean (Gabapentin), 2002 15.91[0.11; 330.07]51not evaluable Neural Tube Defects Morrow (Gabapentin) (Controls exposed to Lamotrigine, sick), 2006 17.05[0.28; 176.78]131not evaluable Oro-facial clefts Morrow (Gabapentin) (Controls exposed to Lamotrigine, sick), 2006 17.05[0.28; 176.78]131not evaluable Growth parameters and prematurity Preterm (< 37 weeks) Arkilo (Gabapentin), 2015 Miškov (Gabapentin) (Controls unexposed, sick), 2016 210.63[0.54; 209.24]43not evaluable Neonatal disorders Withdrawal syndrome / Neonatal abstinence syndrome / Poor neonatal adaptation 0----- Long term consequences Behavioral disorders Bromley (Gabapentin), 2016 11.10[0.38; 3.18]-14not evaluable Emotional disorders Bromley (Gabapentin), 2016 11.13[0.39; 3.28]-14not evaluable Intrauterine deaths Intrauterine deaths (as a whole or unspecified) Arkilo (Gabapentin), 2015 Miškov (Gabapentin) (Controls unexposed, sick), 2016 Vajda (Gabapentin) (Controls unexposed, sick), 2018 34.41[0.49; 39.98]317not evaluable Early intrauterine death (< 22 weeks) Arkilo (Gabapentin), 2015 Miškov (Gabapentin) (Controls unexposed, sick), 2016 24.64[0.23; 93.20]23not evaluable Elective/induced termination of pregnancy Miškov (Gabapentin) (Controls unexposed, sick), 2016 12.33[0.03; 182.92]-2not evaluable Therapeutic terminations of pregnancy Miškov (Gabapentin) (Controls unexposed, sick), 2016 12.33[0.03; 182.92]-2not evaluable Late intrauterine deaths (> 22 weeks) Arkilo (Gabapentin), 2015 147.00[0.38; 5814.69]-1not evaluable Neuro-developmental disorders Neuro-developmental disorders (as a whole) Dean (Gabapentin), 2002 Arkilo (Gabapentin), 2015 27.99[0.44; 143.69]62not evaluable ADHD (Attention deficit hyperactivity disorder): Risk Bromley (Gabapentin), 2016 10.87[0.30; 2.52]-14not evaluable ASD (Autism spectrum disorder): Diagnosis Wood (Gabapentin), 2015 117.00[0.13; 2166.90]-1not evaluable ASD (Autism spectrum disorder): Risk Wood (Gabapentin), 2015 117.00[0.13; 2166.90]-1not evaluable Cognitive developmental disorders/delay (> 6 years old) Bromley (Gabapentin), 2016 11.33[0.13; 13.89]414not evaluable Language disorders/delay Bromley (Gabapentin), 2016 10.98[0.10; 9.53]514not evaluable0.0100.01.0

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons